February 7, 2022 02:13 PM ESTUpdated 05:24 PM
Pharma

As­traZeneca ter­mi­nates US pen­sion plan — will oth­er phar­mas fol­low?

Paul Schloesser

Associate Editor

As­traZeneca’s US sub­sidiary is ax­ing its $1.3 bil­lion-dol­lar pen­sion plan this year, mark­ing an end of an era as an­oth­er group of re­tire­ment funds at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times